2021年7月5日 · KHK-4083是由日本药企Kyowa Hakko Kirin和Amgen共同开发的全人源化单抗药物，为OX40的配体抑制剂。 该产品是利用Kyowa Hakko Kirin独有的技术平台POTELLIGENT®得到的不含岩藻糖的ADCC增强抗体。 目前，主流抗体药物基本为IgG类抗体，在IgG的Fc段具有N-糖链，而糖链的组成和结构影响抗体的结构、效应功能和药代动力学性质。 POTELLIGENT®技术平台通过敲除FUT8（CHO细胞系），去除了IgG糖链中的岩藻糖，在保持细胞稳定性、生长速 …

KHK4083是一种潜在同类首款（first-in-class）抗OX40全人单克隆抗体，目前正开发用于治疗自身免疫性疾病，包括特应性皮炎（AD）。KHK4083由协和麒麟发现，采用该公司获得专利的POTELLIGENT®去岩藻糖基化（defucosylation）技术生产，以增强其抗体依赖性细胞毒 …

2023年1月21日 · Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis

2023年10月9日 · Rocatinlimab（KHK4083）是一种抗OX40单克隆抗体，可抑制和减少表达OX40的活化T细胞的数量。 它是一种人类非岩藻糖基化形式的IgG1抗体，可诱导抗体依赖性细胞毒性，从而具有靶向致病细胞的能力。

Here, we report the results of the phase 1 study of KHK4083, a fully human antimonoclonal antibody specific for OX40. In this study, we aimed to assess the safety and tolerability of a single intravenous or subcutaneous administration of KHK4083 compared with placebo in healthy Japanese and Caucasian subjects and determined the pharmacokinetics ...

2021年2月18日 · KHK4083 is a potential first-in-class, anti-OX40 fully human monoclonal antibody for the treatment of autoimmune diseases, including atopic dermatitis. KHK4083 was first discovered by Kyowa Kirin, and is produced with the Company’s patented POTELLIGENT ® defucosylation technology to enhance its antibody dependent cellular cytotoxicity (ADCC ...

Rocatinlimab（KHK4083）是一种抗OX40 单克隆抗体 ，它能够抑制并降低表达OX40的活化T细胞的数量。 该药物是一种非岩藻糖基化的 IgG1抗体 ，能够引发细胞毒性，具有靶向致病细胞的能力。

2021年6月1日 · KHK4083 is an anti-OX40 fully human monoclonal antibody discovered by Kyowa Kirin and engineered with Kyowa Kirin's patented POTELLIGENT® defucosylation technology to enhance its antibody-dependent cellular cytotoxicity (ADCC) activity. KHK4083 has been shown to selectively deplete activated T cells that are critical in the development of ...

2022年12月13日 · Rocatinlimab (KHK4083/AMG 451) is an anti-OX40 human monoclonal antibody that inhibits and reduces the number of OX40-expressing pathogenic T cells, responsible for driving systemic and local inflammatory responses.

KHK4083 is a fully human monoclonal antibody against OX40. Objective: The primary aim of this first-in-human phase 1 study was to determine the safety and tolerability of ascending single doses of KHK4083 in patients with mild to moderate plaque psoriasis. Secondary aims were to determine the pharmacokinetics and immunogenicity of KHK4083, and ...